Pneumologie 2023; 77(S 01): S5
DOI: 10.1055/s-0043-1760878
Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with
Unresectable Stage III NSCLC (PACIFIC-9)
Authors
-
F Griesinger
1
Pius-Hospital Oldenburg; University Medicine Oldenburg; Hematology/Oncology, Internal
Medicine-Oncology
-
L Barlesi
2
Gustave Roussy, Villejuif, France; Aix Marseille University, Cnrs, Inserm, Crcm
-
S Goldberg
3
Yale School of Medicine and Yale Cancer Center
-
H Mann
4
Astrazeneca
-
A Gopinathan
4
Astrazeneca
-
M Newton
4
Astrazeneca
-
C Aggarwal
5
Abramson Cancer Center, University of Pennsylvania
-
M Heilmann
6
Krh Klinikum Siloah
